Gregory T Everson
Overview
Explore the profile of Gregory T Everson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
137
Citations
4672
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Harrison S, Mayo P, Hobbs T, Zhao C, Canizares C, Foster R, et al.
Liver Int
. 2025 Feb;
45(3):e70036.
PMID: 39982177
Background And Aims: Rencofilstat inhibits cyclophilin to reduce hepatic inflammation and fibrosis, which, in turn, could improve liver function and reduce portal-systemic shunting. Since HepQuant quantifies liver function and portal-systemic...
2.
Kittelson J, McRae M, Everson G
Eur J Intern Med
. 2024 Dec;
132:160-163.
PMID: 39638649
No abstract available.
3.
Chavan S, McRae M, Pitts K, Everson G
PLoS One
. 2024 Nov;
19(11):e0313006.
PMID: 39576797
Aims: The dual oral cholate challenge test (DuO) quantifies liver function and portal-systemic shunting. Herein we report the economic impact of the use of the DuO Disease Severity Index (DSI)...
4.
Shiffman M, Reddy K, Leise M, Qureshi K, Smith A, Helmke S, et al.
Aliment Pharmacol Ther
. 2024 Nov;
61(1):75-87.
PMID: 39523681
Background: The accuracy of current criteria for ruling out large oesophageal varices (LEV) and other endoscopic lesions of portal hypertension (PH) may be compromised by obesity and MASLD/MASH. Aims: In...
5.
Helmke S, Kittelson J, Imperial J, McRae M, Everson G
Gastro Hep Adv
. 2024 Sep;
3(7):944-953.
PMID: 39286620
Background And Aims: We quantified hepatic functional impairment using quantitative function tests and linked severity of functional impairment to liver-related complications and outcome in primary sclerosing cholangitis. Methods: Forty-seven patients...
6.
Helmke S, McRae M, Christians U, Shokati T, Everson G
J Appl Lab Med
. 2024 Aug;
9(6):1028-1039.
PMID: 39150903
Background: Current methods for evaluating liver health rely on nonspecific blood tests, elastography surrogates for fibrosis, and invasive procedures, none of which directly measure liver function and physiology. Herein we...
7.
Hassanein T, Keaveny A, Mantry P, Smith A, McRae M, Kittelson J, et al.
Aliment Pharmacol Ther
. 2024 Jun;
60(3):405-406.
PMID: 38924551
No abstract available.
8.
Lawitz E, Ertle J, Schoelch C, Gashaw I, McRae M, Helmke S, et al.
Liver Transpl
. 2024 Jun;
30(10):982-990.
PMID: 38869987
New methods for measuring hepatic improvement in clinical trials and the clinic are needed. One new method, HepQuant SHUNT, detected dose-dependent improvements in hepatic function and portal physiology in the...
9.
Hassanein T, Keaveny A, Mantry P, Smith A, McRae M, Kittelson J, et al.
Aliment Pharmacol Ther
. 2024 May;
60(2):246-256.
PMID: 38778481
Background: The quantitative HepQuant SHUNT test of liver function and physiology generates a disease severity index (DSI) that correlates with risk for clinical complications, such as large oesophageal varices (LEVs)....
10.
Kanodia J, Giovinazzo H, Yates W, Bourdet D, McRae M, Helmke S, et al.
Clin Pharmacol Ther
. 2024 Apr;
116(1):186-193.
PMID: 38654484
HepQuant tests quantify liver function from clearance of deuterium- and 13C-labeled cholates administered either intravenously and orally (SHUNT) or orally (DuO). Hepatic impairment studies have relied on clinical or laboratory...